Anaplastic thyroid carcinoma
- PMID: 22783225
- PMCID: PMC3389605
- DOI: 10.3389/fendo.2012.00084
Anaplastic thyroid carcinoma
Abstract
Thyroid cancers represent about 1% of all human cancers. Differentiate thyroid carcinomas (DTCs), papillary and follicular cancers, are the most frequent forms, instead Anaplastic Thyroid Carcinoma (ATC) is estimated to comprise 1-2% of thyroid malignancies and it accounts for 14-39% of thyroid cancer deaths. The annual incidence of ATC is about one to two cases/million, with the overall incidence being higher in Europe (and area of endemic goiter) than in USA. ATC has a more complex genotype than DTCs, with chromosomal aberrations present in 85-100% of cases. A small number of gene mutations have been identified, and there appears to be a progression in mutations acquired during dedifferentiation. The mean survival time is around 6 months from diagnosis an outcome that is frequently not altered by treatment. ATC presents with a rapidly growing fixed and hard neck mass, often metastatic local lymph nodes appreciable on examination and/or vocal paralysis. Symptoms may reflect rapid growth of tumor with local invasion and/or compression. The majority of patients with ATC die from aggressive local regional disease, primarily from upper airway respiratory failure. For this reason, aggressive local therapy is indicated in all patients who can tolerate it. Although rarely possible, complete surgical resection gives the best chance of long-term control and improved survival. Therapy options include surgery, external beam radiation therapy, tracheostomy, chemotherapy, and investigational clinical trials. Multimodal or combination therapy should be useful. In fact, surgical debulking of local tumor, combined with external beam radiation therapy and chemotherapy as neoadjuvant (before surgery) or adjuvant (after surgery) therapy, may prevent death from local airway obstruction and as best may slight prolong survival. Investigational clinical trials in phase I or in phase II are actually in running and they include anti-angiogenetic drugs, multi-kinase inhibitor drugs.
Keywords: anaplastic; cancer; genetic alteration; prognosis; therapy; thyroid; treatment; tumor.
Similar articles
-
Anaplastic thyroid cancer: prevalence, diagnosis and treatment.Minerva Endocrinol. 2008 Dec;33(4):341-57. Minerva Endocrinol. 2008. PMID: 18923370 Review.
-
Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options.World J Clin Oncol. 2011 Mar 10;2(3):150-7. doi: 10.5306/wjco.v2.i3.150. World J Clin Oncol. 2011. PMID: 21611089 Free PMC article.
-
Anaplastic thyroid carcinoma in ecuador: analysis of prognostic factors.Int Surg. 2001 Apr-Jun;86(2):117-21. Int Surg. 2001. PMID: 11918236
-
Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.Thyroid. 2019 Aug;29(8):1036-1043. doi: 10.1089/thy.2019.0133. Thyroid. 2019. PMID: 31319771 Free PMC article.
-
[Radiation therapy in thyroid cancer].Cancer Radiother. 2013 Jun;17(3):233-43; quiz 255-6, 258. doi: 10.1016/j.canrad.2012.12.003. Epub 2013 Feb 8. Cancer Radiother. 2013. PMID: 23763764 Review. French.
Cited by
-
Thyroid Cancer Stem-Like Cells: From Microenvironmental Niches to Therapeutic Strategies.J Clin Med. 2021 Apr 1;10(7):1455. doi: 10.3390/jcm10071455. J Clin Med. 2021. PMID: 33916320 Free PMC article. Review.
-
Anaplastic Thyroid Carcinoma with Gastric Metastasis.Curr Health Sci J. 2018 Jul-Sep;44(3):294-298. doi: 10.12865/CHSJ.44.03.14. Epub 2018 Jul 15. Curr Health Sci J. 2018. PMID: 30647951 Free PMC article.
-
Long-term results of radiotherapy in anaplastic thyroid cancer.Radiat Oncol. 2014 Mar 31;9(1):90. doi: 10.1186/1748-717X-9-90. Radiat Oncol. 2014. PMID: 24685141 Free PMC article.
-
Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer.Cancer. 2020 Jan 15;126(2):444-452. doi: 10.1002/cncr.32548. Epub 2019 Oct 8. Cancer. 2020. PMID: 31593317 Free PMC article.
-
Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models.PLoS One. 2018 Nov 12;13(11):e0207152. doi: 10.1371/journal.pone.0207152. eCollection 2018. PLoS One. 2018. PMID: 30419054 Free PMC article.
References
-
- Aiello A., Pandini G., Frasca F., Conte E., Murabito A., Sacco A., Genua M., Vigneri R., Belfiore A. (2006). Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology 147, 4463–447510.1210/en.2005-1610 - DOI - PubMed
LinkOut - more resources
Full Text Sources
Research Materials